{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:06:48Z","timestamp":1780549608361,"version":"3.54.1"},"reference-count":15,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the long-term outcomes of patients with moderate-severe pediatric systemic lupus erythematosus (pSLE) treated with systematic administration of combination rituximab (RTX) and cyclophosphamide (CYC) at our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderate-severe pSLE treated with the combination RTX\/CYC therapy between 2013 and 2023 at a single center were included. Steroid exposure, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, and Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) damage indices were collected as primary outcomes. We also reviewed the literature of the use of RTX\/CYC therapy in pSLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven patients received RTX\/CYC therapy in our cohort. Six of 11 patients (55%) were Black. All patients achieved sustained low disease activity as defined by SLEDAI score less than 4 and prednisone dose less than 8\u00a0mg\/day. There was no statistically significant change in the SLICC\/ACR damage index over time. Positive clinical outcomes were observed in all racial groups. Two of 11 patients (18%) required hemodialysis, with one requiring a transplant. Other adverse effects included anaphylaxis and cytopenias. Several reports of use of RTX\/CYC therapy were identified in our literature search. Our cohort had a more racially diverse cohort compared to other studies identified in our literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study supports the use of rituximab and cyclophosphamide use in patients with pSLE and demonstrates its efficacy among a racially diverse cohort over the long-term follow-up period. Our study has important limitations, and larger, prospective randomized clinical trials would allow for improved protocol evaluation and comparison.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033261441392","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:23:02Z","timestamp":1775661782000},"page":"842-850","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of patients with moderate-severe pediatric systemic lupus erythematosus treated with combination rituximab and cyclophosphamide therapy: A single center cohort experience and review of literature"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8624-5290","authenticated-orcid":false,"given":"Aneesha","family":"Achar","sequence":"first","affiliation":[{"name":"Renaissance School of Medicine at Stony Brook University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyton","family":"Houser","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine at Stony Brook University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Cherian","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine at Stony Brook University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Nuruzzaman","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine at Stony Brook University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-00985-0"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00457-z"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320982668"},{"key":"e_1_3_4_5_2","volume-title":"Cyclophosphamide","author":"Ogino MH","year":"2025","unstructured":"Ogino MH, Tadi P. Cyclophosphamide. StatPearls, 2025."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110172"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00449-2"},{"issue":"3","key":"e_1_3_4_8_2","first-page":"20140114","article-title":"Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide","volume":"12","author":"Lehman TJ","year":"2014","unstructured":"Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12(3): 20140114. https:\/\/doi.org\/10.1186\/1546-0096-12-3","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-11-25"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2896-8"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307081118"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21351"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-012-0720-5"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940416"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033251330094"},{"key":"e_1_3_4_16_2","volume-title":"Chimeric antigen receptor T-Cell therapy","author":"Zhang C","year":"2025","unstructured":"Zhang C, Durer S, Thandra KC, et al. Chimeric antigen receptor T-Cell therapy StatPearls. 2025."}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261441392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033261441392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261441392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:29:51Z","timestamp":1780547391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033261441392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/09612033261441392"],"URL":"https:\/\/doi.org\/10.1177\/09612033261441392","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]}}}